Edesa Biotech (EDSA) Competitors $2.46 +0.07 (+2.71%) Closing price 03:55 PM EasternExtended Trading$2.46 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EDSA vs. CVM, ELYM, OSTX, ALGS, PRLD, LIMN, JMAC, APLT, INKT, and VNRXShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include CEL-SCI (CVM), Eliem Therapeutics (ELYM), OS Therapies (OSTX), Aligos Therapeutics (ALGS), Prelude Therapeutics (PRLD), Liminatus Pharma (LIMN), Maxpro Capital Acquisition (JMAC), Applied Therapeutics (APLT), MiNK Therapeutics (INKT), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Its Competitors CEL-SCI Eliem Therapeutics OS Therapies Aligos Therapeutics Prelude Therapeutics Liminatus Pharma Maxpro Capital Acquisition Applied Therapeutics MiNK Therapeutics VolitionRx CEL-SCI (NYSE:CVM) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Do institutionals and insiders believe in CVM or EDSA? 12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 9.9% of CEL-SCI shares are held by insiders. Comparatively, 22.6% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, CVM or EDSA? Edesa Biotech is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$9.77-1.01Edesa BiotechN/AN/A-$6.17M-$1.32-1.87 Do analysts rate CVM or EDSA? Edesa Biotech has a consensus price target of $5.00, indicating a potential upside of 102.84%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Is CVM or EDSA more profitable? Edesa Biotech's return on equity of -162.95% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% Edesa Biotech N/A -162.95%-60.33% Which has more volatility & risk, CVM or EDSA? CEL-SCI has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Does the media favor CVM or EDSA? In the previous week, CEL-SCI had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for CEL-SCI and 2 mentions for Edesa Biotech. CEL-SCI's average media sentiment score of 1.54 beat Edesa Biotech's score of 0.95 indicating that CEL-SCI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CEL-SCI 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEdesa Biotech beats CEL-SCI on 9 of the 13 factors compared between the two stocks. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.35M$3.10B$5.74B$10.24BDividend YieldN/A2.32%5.69%4.59%P/E Ratio-1.8721.3874.9326.41Price / SalesN/A244.04457.2789.16Price / CashN/A44.4425.8129.91Price / Book4.049.6413.256.28Net Income-$6.17M-$53.20M$3.29B$270.38M7 Day Performance1.86%0.44%0.47%2.70%1 Month Performance10.54%4.26%4.60%5.99%1 Year Performance-43.58%9.43%73.42%25.94% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech1.4499 of 5 stars$2.47+2.7%$5.00+102.8%-43.9%$17.35MN/A-1.8720Gap UpCVMCEL-SCI1.3473 of 5 stars$10.35-1.3%N/A-73.3%$71.23MN/A-21.5643Positive NewsShort Interest ↓ELYMEliem TherapeuticsN/A$2.39+2.6%N/A-73.4%$71.11MN/A-4.519News CoverageOSTXOS Therapies2.0734 of 5 stars$2.24+1.8%$18.00+703.6%-34.6%$70.89MN/A-2.84N/AAnalyst ForecastALGSAligos Therapeutics3.9816 of 5 stars$11.11-2.0%$50.00+350.0%-31.1%$69.76M$3.94M-0.5690Positive NewsAnalyst ForecastPRLDPrelude Therapeutics3.1797 of 5 stars$1.25+1.6%$4.00+220.0%-59.2%$69.62M$7M-0.76120LIMNLiminatus PharmaN/A$2.31-13.5%N/AN/A$69.46MN/A0.00N/APositive NewsJMACMaxpro Capital AcquisitionN/A$5.16-5.8%N/A+4,922.1%$69.29MN/A0.002,021APLTApplied Therapeutics4.0521 of 5 stars$0.44-7.1%$6.10+1,285.4%-91.4%$68.25M$460K-0.9830Positive NewsINKTMiNK Therapeutics3.5999 of 5 stars$15.83+7.0%$37.50+136.9%+85.7%$66.94MN/A-5.5030Positive NewsShort Interest ↓VNRXVolitionRx2.1525 of 5 stars$0.61+1.5%$3.50+472.8%-3.5%$65.74M$1.32M-1.7080Gap Up Related Companies and Tools Related Companies CVM Competitors ELYM Competitors OSTX Competitors ALGS Competitors PRLD Competitors LIMN Competitors JMAC Competitors APLT Competitors INKT Competitors VNRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDSA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDSA Stock Alerts